Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer Journal Article
| Authors: | Berger, M. Z.; Kris, M. G.; Gralla, R. J.; Marks, L. D.; Potanovich, L. M.; Dimaggio, J. J.; Heelan, R. T. |
| Article Title: | Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer |
| Abstract: | Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer. |
| Keywords: | adult; clinical article; aged; antineoplastic agent; phase 2 clinical trial; leukopenia; lung non small cell cancer; thrombocytopenia; intravenous drug administration; phlebitis; amonafide; human; male; female; article |
| Journal Title: | American Journal of Clinical Oncology |
| Volume: | 14 |
| Issue: | 2 |
| ISSN: | 0277-3732 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 1991-04-01 |
| Start Page: | 124 |
| End Page: | 126 |
| Language: | English |
| DOI: | 10.1097/00000421-199104000-00006 |
| PUBMED: | 1851387 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 27 September 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work